Comparative Pharmacology
Head-to-head clinical analysis: DIUCARDIN versus HYDROCHLOROTHIAZIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUCARDIN versus HYDROCHLOROTHIAZIDE INTENSOL.
DIUCARDIN vs HYDROCHLOROTHIAZIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic